Trial · NCT07894705
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 38
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean latency from diagnosis of hypertensive disorders of pregnancy (HDP) to delivery (continuous, mean with standard deviation) | from randomization to delivery | The number of days from randomization to delivery will be analyzed as a continuous variable |
| Secondary | Blood pressure control (continuous, mean with standard deviation) | from randomization to delivery | BP control will be analyzed as mean systolic and diastolic blood pressures; frequency of acute treatment (oral or IV) of severe range elevated BPs |
| Secondary | Serum Soluble fms-like tyrosine kinase 1 / placental growth factor (sFlt-1/PlGF) (log ratio) | from randomization to delivery | Weekly serum sFlt-1/PlGF will be obtained from randomization until delivery. The clinical care team will be blinded to the results of this test as this is not part of our institutional protocol for inpatient management of HDP. The results will be analyzed at the conclusion of the study. |
| Secondary | The frequency of hemolysis, elevated liver enzymes, low platelets (HELLP) | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of placental abruption | from randomization to delivery | |
| Secondary | Frequency of eclampsia | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of stroke | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of MI or angina | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of heart failure | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of intensive care unit (ICU) admission or intubation | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of readmission within 42 days postpartum | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of maternal death | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of encephalopathy | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of pulmonary edema | from randomization through 6 weeks postpartum | |
| Secondary | Frequency of Renal Failure | from randomization through 6 weeks postpartum | |
| Secondary | Indication for delivery | at delivery | The indication for delivery will be categorized as the following non-reassuring fetal status, uncontrolled HTN, worsening symptoms/labs). |
| Secondary | Mode of delivery | at delivery | The mode of delivery will be categorized as normal spontaneous vaginal delivery (NSVD), forceps assisted vaginal delivery (FAVD), vacuum assisted vaginal delivery (VAVD), C-section. |
| Secondary | Global health status (PRO) per the PRO Measurement Information System (PROMIS Global-10) (continuous, mean with standard deviation) | from 4 to 6 weeks postpartum | The PRO Measurement Information System (PROMIS Global-10) is a validated survey of patient-reported outcome measure to assess overall wellbeing. This survey will be administered from 4 to 6 weeks postpartum. |
| Secondary | Birth experience satisfaction per Birth Satisfaction Scale- Revised (BSS-R (continuous, mean with standard deviation) | from delivery to 6 weeks postpartum | The Birth Satisfaction Survey- Revised (BSS-R) is a validated patient satisfaction survey describing L\&D birthing experiences. This survey will be administered at any time from delivery through 6 weeks postpartum. |
| Secondary | Maternal infant bonding per maternal infant bonding scale (MIBS) (continuous, mean with standard deviation) | from 4 to 6 weeks postpartum | The maternal infant bonding scale (MIBS) is a validated is a validated survey of patient-reported outcome measure describing a mother's early emotional feelings and potential bonding challenges with her newborn. This survey will be administered from 4 to 6 weeks postpartum. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07894705/registered